Amryt Pharma (AMYT) to Release Quarterly Earnings on Thursday

Amryt Pharma (NASDAQ:AMYT – Get Rating) will issue its quarterly earnings data before the market opens on Thursday, August 4th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Amryt Pharma (NASDAQ:AMYT – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). The business had revenue of $59.13 million for the quarter, compared to the consensus estimate of $57.48 million. Amryt Pharma had a negative net margin of 6.91% and a positive return on equity of 3.65%. During the same period in the prior year, the firm earned ($0.09) earnings per share. On average, analysts expect Amryt Pharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amryt Pharma Price Performance

NASDAQ AMYT opened at $7.47 on Thursday. The company has a market cap of $477.80 million, a PE ratio of -82.99 and a beta of 0.30. Amryt Pharma has a 52 week low of $5.61 and a 52 week high of $12.45. The company has a quick ratio of 1.04, a current ratio of 1.88 and a debt-to-equity ratio of 0.59. The firm’s 50-day simple moving average is $7.42 and its two-hundred day simple moving average is $8.18.

Institutional Investors Weigh In On Amryt Pharma

Institutional investors and hedge funds have recently modified their holdings of the company. Hsbc Holdings PLC purchased a new stake in shares of Amryt Pharma in the first quarter worth about $202,000. Renaissance Technologies LLC lifted its holdings in shares of Amryt Pharma by 44.1% in the first quarter. Renaissance Technologies LLC now owns 25,800 shares of the company’s stock worth $213,000 after buying an additional 7,900 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Amryt Pharma by 120.2% in the first quarter. Bank of America Corp DE now owns 68,779 shares of the company’s stock worth $569,000 after buying an additional 37,542 shares in the last quarter. Woodline Partners LP lifted its holdings in shares of Amryt Pharma by 262.7% in the first quarter. Woodline Partners LP now owns 480,363 shares of the company’s stock worth $3,973,000 after buying an additional 347,925 shares in the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in shares of Amryt Pharma in the first quarter worth about $8,862,000. 56.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, SVB Leerink reaffirmed an “outperform” rating and set a $19.00 price objective (up from $18.00) on shares of Amryt Pharma in a report on Friday, June 24th.

Amryt Pharma Company Profile

(Get Rating)

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia.